Pacira BioSciences was downgraded from Buy to Hold by Needham following Viatris's announcement to acquire the company for $36.50 per share, valuing it at about $1.65 billion. The deal is expected to close by late 2026 and will enhance Viatris's portfolio with Pacira's patented pain medicines. Despite a 44% rally in Pacira's stock price, options market activity shows bearish sentiment, reflecting some investor caution ahead of the deal's completion. Pacira reported strong financials with $746 million in revenue and $177 million in adjusted EBITDA for the year ending June 2026.
While Pacira BioSciences is set for acquisition at $36.50 per share, Viatris shares on Pluang trade at $17.12 as of Oct 09, 2026 00:31 WIB, down 2.12% for the day. Viatris is closer to its 52-week high of $18.27 than its low of $9.74, showing relative strength despite the dip. The stock's market cap stands at $20.12 billion, reflecting a much larger scale compared to Pacira's $1.65 billion valuation in the deal.
